Answers are grounded in this paper and cite their sources.
Bosentan, a dual endothelin receptor antagonist for pulmonary arterial hypertension (PAH), is vulnerable to drug-drug interactions (DDI) mediated by cytochrome P450 (CYP450) enzymes. We elucidated the effects of lopinavir and adagrasib on bosentan metabolism using rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP2C9*1 (rCYP2C9), complemented by pharmacokinetics in rats and molecular dynamics (MD). In RLM, lopinavir and adagrasib inhibited bosentan metabolism with half-maximal inhibitory concentrations (IC 50 ) of 4.86 μM and 8.41 μM, respectively, displaying mixed and competitive inhibition mechanisms, respectively. In HLM, lopinavir and adagrasib exhibited noncompetitive and mixed inhibition mechanism with IC 50 of 27.75 and 15.16 μM, respectively. In rCYP2C9, both were noncompetitive inhibition mechanism with IC 50 of 34.55, 3.65 μM, respectively. In vivo, co-administration of lopinavir and adagrasib with bosentan, the AUC (0-t) and AUC (0-∞) of bosentan were increased by 107.2% and 176.6%, 106.8% and 176.1%, respectively, and t 1/2 was increased by 52.4% and 50.8%, respectively. For hydroxybosentan, AUC (0-t) and AUC (0-∞) were increased by 109.0% and 109.2% with adagrasib, accompanied by a 56.2% reduction in CL z/F under adagrasib co-administration. MD simulations suggested that lopinavir and adagrasib might inhibit CYP2C9-mediated bosentan metabolism by altering its positioning relative to the heme catalytic center. These findings underlined the potential DDI between bosentan and adagrasib or lopinavir, warranting cautious clinical co-administration.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: